Novartis AG (OTCMKTS:NVSEF)

Stock Price: $86.08

-1.495 (-1.71%)

Updated Feb 2, 2023 09:00 PM GMT+0000

Featured app

Invest now

<p>79% of retail CFD accounts lose money</p>

Overview

Financials

Statistics

Profile

Chart

Market Cap	206.96B
Revenue	0
Gross Profit	0
Shares Out	2.40B
EPS (ttm)
PE Ratio	0.0000
Forward PE	0.0000
Dividend Rate (ttm)	0.0000
Dividend Yield	0.0000

Trading Day	Feb 2
Last Price	$86.08
Previous Close	$87.57
Change ($)	-1.495
Change (%)	-1.71%
Day's Open	86.075
Day's Range	Market Closed
Day's Volume	300.30K
52 Week Range	72.98 - 93.58

About Novartis AG

News

Is Eli Lilly or Novartis the better buy after Q3 results? October 26, 2021

Novartis stock price falls to 7-month lows on lower sales October 27, 2020

Novartis AG reports a 4% decline in net profit in the second quarter July 21, 2020

Quick info

Country

Industry

Pharmaceutical Preparation Manufacturing

Sector

Manufacturing

Address

Lichtstrasse 35
Basel
Basel Stadt
4056

Phone

41613241111

Website

https://www.novartis.com/

Ticker Symbol

NVSEF

Exchange

OTC Markets Group

Reporting Currency

USD

Novartis AG income statements (2020) (USD)

	September 2020	June 2020	March 2020
Total Revenue	12.26B	11.35B	12.28B
Cost of Revenue	3.75B	3.43B	3.72B
Gross Profit	8.51B	7.92B	8.56B
Research & Development	2.15B	2.44B	2.06B
Selling General & Admin	3.42B	3.37B	3.49B
Operating Expense	9.32B	9.24B	9.27B
Operating Income	2.97B	2.14B	3.05B
Other Income Expense Net	-782M	-39M	-550M
EBIT	2.97B	2.14B	3.05B
Interest Income	209M	220M	239M
Pretax Income	2.18B	2.11B	2.50B
Income Tax	478M	421M	448M
Minority Interest	-3M	0	-3M
Net Income	1.94B	1.87B	2.18B
Net Income Basic	1.94B	1.87B	2.18B

Novartis AG income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	12.40B	12.17B	11.76B	11.16B
Cost of Revenue	3.99B	3.78B	3.41B	3.25B
Gross Profit	8.41B	8.40B	8.36B	7.91B
Research & Development	2.85B	2.20B	2.05B	2.30B
Selling General & Admin	3.91B	3.55B	3.59B	3.33B
Operating Expense	10.75B	9.52B	9.04B	8.88B
Operating Income	1.74B	2.72B	2.73B	2.29B
Other Income Expense Net	-131M	-569M	-270M	-228M
EBIT	1.74B	2.72B	2.73B	2.29B
Interest Income	203M	216M	205M	226M
Pretax Income	1.61B	2.15B	2.46B	2.06B
Income Tax	630M	366M	525M	272M
Minority Interest	4M	-1M	1M	1M
Net Income	1.13B	2.04B	6.80B	1.77B
Net Income Basic	1.13B	2.04B	6.80B	1.77B

Novartis AG income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	13.27B	12.78B	13.16B	12.69B
Cost of Revenue	4.93B	4.65B	4.48B	4.36B
Gross Profit	8.34B	8.13B	8.68B	8.34B
Research & Development	2.40B	2.28B	2.28B	2.12B
Selling General & Admin	4.40B	3.95B	4.19B	3.92B
Operating Expense	11.73B	10.88B	10.95B	10.40B
Operating Income	1.94B	2.24B	2.51B	2.53B
Other Income Expense Net	-812M	-512M	-219M	-274M
EBIT	1.94B	2.24B	2.51B	2.53B
Interest Income	254M	235M	244M	224M
Pretax Income	1.12B	1.73B	2.29B	2.26B
Income Tax	70M	319M	451M	381M
Minority Interest	-1M	1M	0	3M
Net Income	1.20B	1.62B	7.77B	2.03B
Net Income Basic	1.20B	1.62B	7.77B	2.03B

Novartis AG income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	12.92B	12.41B	12.24B
Cost of Revenue	4.49B	4.32B	4.26B
Gross Profit	8.43B	8.09B	7.98B
Research & Development	2.50B	2.24B	2.06B
Selling General & Admin	4.04B	3.68B	3.81B
Operating Expense	11.03B	10.24B	10.13B
Operating Income	2.13B	2.45B	2.37B
Other Income Expense Net	-247M	-278M	-268M
EBIT	2.13B	2.45B	2.37B
Interest Income	208M	197M	192M
Pretax Income	1.89B	2.17B	2.10B
Income Tax	325M	353M	336M
Minority Interest	0	2M	-1M
Net Income	1.98B	2.08B	1.98B
Net Income Basic	1.98B	2.08B	1.98B

Novartis AG balance sheet (2020) (USD)

	September 2020	June 2020	March 2020
Current Cash	8.99B	5.92B	4.53B
Receivables	8.07B	7.64B	8.54B
Inventory	7.14B	6.90B	6.40B
Current Assets	28.97B	23.88B	23.10B
Other Current Assets	2.67B	2.73B	2.93B
Short Term Investments	1.88B	376M	445M
Long Term Investments	11.60B	11.05B	10.52B
Property/Plant Equipment	13.34B	13.60B	13.56B
Good Will	N.A	N.A	N.A
Intangible Assets	36.88B	36.67B	37.45B
Tangible Assets (Net)	24.95B	24.71B	21.97B
Other Assets	850M	866M	0.99B
Total Assets	129.68B	123.76B	123.10B
Accounts Payable	4.71B	4.82B	4.83B
Other Current Liabilities	14.43B	12.86B	12.96B
Total Current Liabilities	31.84B	29.38B	31.29B
Total Liabilities	75.12B	69.88B	72.12B
Long Term Debt	28.18B	25.65B	25.49B
Current Long Term Debt	267M	258M	249M
Minority Interest	-3M	0	-3M
Common Stock	2.27B	2.29B	2.29B
Treasury Stock	44M	37M	68M
Retained Earnings	57.40B	57.50B	55.36B
Capital Surplus	N.A	N.A	N.A
Shareholder Equity	54.48B	53.81B	50.90B
Other Liabilities	N.A	N.A	N.A

Novartis AG balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	11.11B	8.38B	9.99B	6.81B
Receivables	8.30B	7.83B	7.97B	7.61B
Inventory	5.98B	6.12B	6.09B	5.73B
Current Assets	29.50B	26.68B	28.32B	52.45B
Other Current Assets	2.90B	3.77B	3.64B	31.76B
Short Term Investments	334M	339M	344M	305M
Long Term Investments	10.43B	11.06B	11.64B	10.12B
Property/Plant Equipment	13.75B	13.56B	12.29B	12.42B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	28.79B	29.69B	27.22B	27.02B
Tangible Assets (Net)	-51.29B	26.22B	24.89B	20.93B
Other Assets	897M	689M	2.47B	2.35B
Total Assets	118.41B	115.97B	116.29B	137.95B
Accounts Payable	5.42B	4.67B	4.75B	4.64B
Other Current Liabilities	13.55B	12.94B	15.01B	41.94B
Total Current Liabilities	28.26B	28.22B	30.11B	56.13B
Total Liabilities	62.86B	63.37B	64.79B	90.64B
Long Term Debt	22.06B	21.83B	22.12B	22.89B
Current Long Term Debt	2.25B	266M	294M	273M
Minority Interest	4M	-1M	1M	1M
Common Stock	2.27B	2.26B	2.29B	2.32B
Treasury Stock	80M	80M	67M	63M
Retained Earnings	59.28B	57.93B	55.65B	51.52B
Capital Surplus	N.A	N.A	N.A	N.A
Shareholder Equity	55.47B	52.52B	51.43B	47.23B
Other Liabilities	N.A	N.A	N.A	N.A

Novartis AG balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	13.27B	14B	12.45B	5.81B
Receivables	8.73B	8.59B	8.80B	8.92B
Inventory	6.96B	6.95B	7.10B	7.23B
Current Assets	35.56B	34.11B	32.07B	33.05B
Other Current Assets	2.98B	3.69B	2.83B	10.29B
Short Term Investments	2.68B	710M	700M	609M
Long Term Investments	9.79B	10.81B	10.36B	10.52B
Property/Plant Equipment	15.70B	15.75B	15.96B	16.68B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	38.72B	37.95B	39.44B	32.12B
Tangible Assets (Net)	-61.41B	42.90B	41.65B	36.97B
Other Assets	1.24B	1.18B	843M	818M
Total Assets	145.65B	142.99B	142.06B	135.52B
Accounts Payable	5.56B	4.97B	5.49B	4.99B
Other Current Liabilities	12.39B	12.49B	11.16B	10.56B
Total Current Liabilities	29.61B	28.33B	27.94B	28.22B
Total Liabilities	66.95B	64.98B	65.16B	64.31B
Long Term Debt	22.47B	22.61B	22.76B	23.20B
Current Long Term Debt	3.19B	N.A	N.A	N.A
Minority Interest	-1M	1M	0	3M
Common Stock	2.31B	2.31B	2.32B	2.33B
Treasury Stock	69M	69M	63M	93M
Retained Earnings	82.19B	80.16B	79.79B	73.50B
Capital Surplus	N.A	N.A	N.A	N.A
Shareholder Equity	78.61B	77.94B	76.82B	71.10B
Other Liabilities	N.A	N.A	N.A	N.A

Novartis AG balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	8.86B	8.81B	7.86B
Receivables	8.60B	8.48B	8.38B
Inventory	6.87B	6.95B	6.90B
Current Assets	28.21B	27.47B	26.54B
Other Current Assets	1.79B	2.61B	2.82B
Short Term Investments	625M	611M	581M
Long Term Investments	16.65B	2.60B	N.A
Property/Plant Equipment	16.46B	16.26B	16.21B
Good Will	N.A	N.A	N.A
Intangible Assets	30B	30.84B	31.47B
Tangible Assets (Net)	-47.76B	40.60B	38.31B
Other Assets	1.20B	26.09B	27.93B
Total Assets	133.23B	134.97B	133.75B
Accounts Payable	5.17B	4.69B	4.69B
Other Current Liabilities	11.31B	13.70B	13.89B
Total Current Liabilities	23.40B	25.38B	26.15B
Total Liabilities	59B	62.60B	63.77B
Long Term Debt	23.22B	23.16B	23B
Current Long Term Debt	359M	N.A	N.A
Minority Interest	0	2M	-1M
Common Stock	2.32B	2.33B	2.09B
Treasury Stock	100M	N.A	N.A
Retained Earnings	77.64B	N.A	N.A
Capital Surplus	N.A	N.A	N.A
Shareholder Equity	74.17B	72.31B	69.92B
Other Liabilities	N.A	N.A	N.A

Novartis AG cash flow (2020) (USD)

	September 2020	June 2020	March 2020
Net Income	1.94B	1.87B	2.18B
Depreciation	1.90B	1.71B	1.41B
Changes in Receivables	-429M	897M	-240M
Changes in Inventories	N.A	N.A	N.A
Cash Change	3.01B	1.38B	-6.58B
Cash Flow	3.49B	3.98B	2.53B
Capital Expenditures	-689.51M	-461.46M	-524M
Investments	-1.42B	75.78M	239M
Investing Activity (other)	-24.3M	-91.26M	-14M
Total Investing Cash Flows	-2.48B	-451.39M	-10.14B
Dividends Paid	-237.48M	-17.45M	-6.99B
Net Borrowings	3.18B	-2.16B	7.60B
Other Financing Cash Flows	2.58M	38.58M	-207M
Cash Flow Financing	1.93B	-2.19B	1.01B
Exchange Rate Effect	70.24M	38.13M	16M

Novartis AG cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	1.13B	2.04B	6.80B	1.77B
Depreciation	1.93B	1.44B	1.04B	1.44B
Changes in Receivables	-475M	147M	-361M	1.12B
Changes in Inventories	N.A	N.A	N.A	N.A
Cash Change	2.77B	-1.67B	3.19B	-6.46B
Cash Flow	3.50B	4.67B	3.10B	2.41B
Capital Expenditures	-647.09M	-590.01M	-450.89M	-629M
Investments	343.18M	525.08M	83.33M	2.24B
Investing Activity (other)	-51.67M	-10.09M	-179.83M	-0.92B
Total Investing Cash Flows	332.09M	-3.42B	22.55M	829M
Dividends Paid	59.85M	-78.9M	19.05M	-6.65B
Net Borrowings	-1.3B	286.07M	-788.68M	-3.15B
Other Financing Cash Flows	-59.06M	23.81M	3.20B	156M
Cash Flow Financing	-1.15B	-2.85B	-157.89K	-9.68B
Exchange Rate Effect	79.36M	-63.94M	75.85M	-22M

Novartis AG cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	1.20B	1.62B	7.77B	2.03B
Depreciation	379.44M	N.A	N.A	1.25B
Changes in Receivables	-142M	218M	115M	-318M
Changes in Inventories	N.A	N.A	N.A	N.A
Cash Change	-754.2M	1.57B	6.57B	-3.05B
Cash Flow	3.62B	4.07B	3.82B	2.51B
Capital Expenditures	-0.95B	-1.04B	-602.24M	-802M
Investments	-2.2B	-3.15M	12.83B	-25M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-4.84B	-875.19M	4.32B	-4.1B
Dividends Paid	-69.07M	-61.21M	130.28M	-6.97B
Net Borrowings	513.63M	-554.36M	-1.09B	5.30B
Other Financing Cash Flows	-39.76M	-11.43M	82.14M	-142M
Cash Flow Financing	479.71M	-1.63B	-1.47B	-1.55B
Exchange Rate Effect	-12.68M	10.68M	-103.55M	80M

Novartis AG cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	1.98B	2.08B	1.98B
Depreciation	471.92M	1.56B	1.38B
Changes in Receivables	-118M	-102M	-146M
Changes in Inventories	N.A	N.A	N.A
Cash Change	-373.44K	0.99B	292.36M
Cash Flow	3.17B	3.76B	3.64B
Capital Expenditures	-0.93B	-480.38M	-607.06M
Investments	871.38M	-18.1M	N.A
Investing Activity (other)	300.28M	-393.91M	-40.86M
Total Investing Cash Flows	-0.96B	-723.97M	-351.16M
Dividends Paid	162.55M	-98.61M	-63.94M
Net Borrowings	-1.59B	-499.1M	-1.16B
Other Financing Cash Flows	-41.28M	38.12M	82.13M
Cash Flow Financing	-2.24B	-2.04B	-3.05B
Exchange Rate Effect	32.51M	-9.34M	51.59M

Novartis AG dividends (USD)

Ex date	Payment date	Record date	Declared date	Amount	Description	Frequency
03-03-2020	05-03-2020	04-03-2020	N.A	2.95	Ordinary Shares (Registered)	Annual
04-03-2019	06-03-2019	05-03-2019	N.A	2.85	Ordinary Shares (Registered)	Annual